ICML 2019 | Durable responses after CD19 CAR-T plus ibrutinib in CLL

Alexandre Hirayama

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses responses after CD19-specific CAR T-cell therapy with concurrent ibrutinib in patients with chronic lymphocytic leukemia (CLL) after prior ibrutinib failure. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video